Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

When to thin blood after brain bleed? new trial seeks answer

NCT ID NCT06753786

Disease control Sponsor: Pirogov Russian National Research Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 200 people who had a bleeding stroke caused by high blood pressure. Doctors want to know if starting blood thinners (heparin) early—within 2 days—or waiting until day 3 is safer and better at preventing blood clots in the legs or lungs. Participants get brain scans and leg ultrasounds to check for clot formation or bleeding expansion.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
heparin (unfractionated or low molecular weight)
What this could lead to
If successful, this could establish the safest time to start blood thinners in bleeding stroke patients to prevent dangerous clots without worsening brain bleeding.
What could go wrong
This is a single-center trial with 200 participants, so results may not apply broadly. Both timing strategies carry bleeding risks, and the study may not find a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * the presence of hypertensive intracerebral hemorrhage Exclusion Criteria: * Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin) * Being on an anticoagulant during preadmission period and on day of hospital admission * Death within the first 2 days after hospital admission * Detection of venous thromboembolism in a patient at the moment of hospital admission * Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin * The presence of a malignancy (cancer) in a patient at the moment of hospital admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep vein thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage pulmonary embolism Venous Thrombosis venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep vein thrombosis Intracerebral hemorrhage Pulmonary embolism Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Moscow City Clinical Hospital named after V.M. Buyanov

    RECRUITING

    Moscow, 115516, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.